about
Antimotility agents for chronic diarrhoea in people with HIV/AIDSThe value of plants used in traditional medicine for drug discoveryNoninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyFiber and functional gastrointestinal disorders.Gastrointestinal Symptoms in HIV-Infected Patients: Female Sex and Smoking as Risk Factors in an Outpatient Cohort in Brazil.Dietary fiber in irritable bowel syndrome (Review)Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.Human Immunodeficiency Virus-Associated Diarrhea: Still an Issue in the Era of Antiretroviral Therapy.Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs.Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDSAssessing HIV and AIDS treatment safety and health-related quality of life among cohort of Malaysian patients: a discussion on methodological approach.Crofelemer, a novel agent for treatment of secretory diarrhea.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons.Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons.In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.The efficacy of calcium carbonate in the treatment of protease inhibitor-induced persistent diarrhea in HIV-infected patients.Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.Global impact of antiretroviral therapy-associated diarrhea.Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study.The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.High-throughput formulation screening system for self-microemulsifying drug delivery.Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
P2860
Q24240888-D226AACB-8463-4852-AF7B-FEEAD025C2C7Q24536929-CE19915D-A895-4A15-91B9-45A006204F50Q30609066-8503AFD4-797F-4554-85A8-A6C1655C140EQ33457556-D776B60C-7F40-4222-9BCB-CC9A43CF3B24Q33469007-982A9192-907E-4B06-8E5C-650B2A0FB6CFQ33470938-2D3B4E0B-BFF6-4D0E-880D-F67F48706B96Q33578024-B4F95B00-B1DE-4F34-A25E-229F317B804CQ34228277-D88AA32B-33B9-4F67-87FC-71940A091207Q34668617-2C8BC15C-161D-450B-BF29-CC39FF0130C3Q35820243-A9D9DD2A-5E43-465B-9E10-B26DB9208C91Q36349701-692EA253-34A6-417E-A501-C799C10A20A2Q37042269-B58705F3-FAF8-4C0F-93B3-F2AD1E35C3EDQ37333388-F4BC0B3B-93F4-4C49-8455-A530B47C0984Q37730305-320BE2E6-3AA9-4963-A072-1A467A3711B0Q37823558-E6941313-7C69-4691-BDE4-9FD1C1FBD2C3Q38144148-375F4EF1-6E5F-42C0-BABA-7CF119A90E7FQ40566104-82AED1D3-5F02-4316-822F-9BBE10315119Q41992855-589CE674-79F2-44FA-849A-D14D41B2F357Q42213902-83BCD3F7-6D31-414D-9DA6-FAC4E55A2099Q42621470-50027652-1CD4-4716-9352-105EA524DD86Q42772430-E65F6991-945E-4FBF-873B-3E305394C6B4Q42772433-EB7E85DA-67DD-4C84-BC99-1A8AFA9C35EBQ42772440-757F8217-ADDB-42CF-81B0-C2A5C64C0ED7Q42933928-4EB69D1A-A8E7-46FD-ADD8-817062FD0530Q43109126-139C4272-049D-4572-9328-B46598F83804Q43504829-43DFD829-458B-4EA6-A1D5-BA5F7C6D400BQ44282746-B6122F92-B5A8-4A12-8ED5-7408909E6200Q45974657-BE644944-F6D0-4465-AA2C-63C07C2C897DQ50702955-FF1BBA84-CD1C-45C6-BA50-5B40931C57CB
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Management of protease inhibitor-associated diarrhea.
@ast
Management of protease inhibitor-associated diarrhea.
@en
type
label
Management of protease inhibitor-associated diarrhea.
@ast
Management of protease inhibitor-associated diarrhea.
@en
prefLabel
Management of protease inhibitor-associated diarrhea.
@ast
Management of protease inhibitor-associated diarrhea.
@en
P2860
P356
P1476
Management of protease inhibitor-associated diarrhea.
@en
P2093
P2860
P304
P356
10.1086/313826
P407
P577
2000-06-14T00:00:00Z